{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:21Z","timestamp":1791176841703,"version":"4.1.0"},"reference-count":40,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"DOI":"10.3201\/eid1402.070499","type":"journal-article","created":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T19:51:59Z","timestamp":1223668319000},"page":"244-251","source":"Crossref","is-referenced-by-count":102,"title":["Cost-effectiveness of Human Papillomavirus Vaccination in the United States"],"prefix":"10.3201","volume":"14","author":[{"given":"Harrell W.","family":"Chesson","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatus U.","family":"Ekwueme","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Saraiya","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E.","family":"Markowitz","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","published-online":{"date-parts":[[2008,2]]},"reference":[{"key":"key-10.3201\/eid1402.070499-201211051415-R1","unstructured":"Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking. Washington: National Academy of Sciences; 2000."},{"key":"key-10.3201\/eid1402.070499-201211051415-R2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: the burden of HPV-related cancers.","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"key-10.3201\/eid1402.070499-201211051415-R3","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"key-10.3201\/eid1402.070499-201211051415-R4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","article-title":"Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis.","volume":"89","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"key-10.3201\/eid1402.070499-201211051415-R5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1086\/505982","article-title":"Genital human papillomavirus infection.","volume":"43","author":"Dunne","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid1402.070499-201211051415-R6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/JCM.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.","volume":"33","author":"Greer","year":"1995","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1363\/3601104","article-title":"The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.","volume":"36","author":"Chesson","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"key":"key-10.3201\/eid1402.070499-201211051415-R8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","article-title":"Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.","volume":"23","author":"Insinga","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"key-10.3201\/eid1402.070499-201211051415-R9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies.","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid1402.070499-201211051415-R10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine.","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"key-10.3201\/eid1402.070499-201211051415-R11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus.","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid1402.070499-201211051415-R12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"key":"key-10.3201\/eid1402.070499-201211051415-R13","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs.","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid1402.070499-201211051415-R14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"key":"key-10.3201\/eid1402.070499-201211051415-R15","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"key-10.3201\/eid1402.070499-201211051415-R16","doi-asserted-by":"crossref","unstructured":"Haddix AC, Teutsch SM, Corso PS, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation, 2nd ed. New York: Oxford University Press; 2003.","DOI":"10.1093\/oso\/9780195148978.001.0001"},{"key":"key-10.3201\/eid1402.070499-201211051415-R17","unstructured":"U.S. Census Bureau. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2005 (NC-EST2005\u201301). Population Division, US Census Bureau; 2006 [cited 2007 Aug 8]. Available from http:\/\/www.census.gov\/popest\/national\/asrh\/NC-EST2005-sa.html"},{"key":"key-10.3201\/eid1402.070499-201211051415-R18","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine.","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid1402.070499-201211051415-R19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R21","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"key-10.3201\/eid1402.070499-201211051415-R22","unstructured":"US Cancer Statistics Working Group. United States cancer statistics: 2003 incidence and mortality. Atlanta: Centers for Disease Control and Prevention and National Cancer Institute; 2006."},{"key":"key-10.3201\/eid1402.070499-201211051415-R23","first-page":"1117","article-title":"The surveillance, epidemiology, and end results program: a national resource.","volume":"8","author":"Hankey","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key-10.3201\/eid1402.070499-201211051415-R24","unstructured":"Watson M, Saraiya M, Weir H, Ahmed F. Leading partnerships to assess the burden of HPV-related cancers. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13\u201317; Atlanta. Atlanta: Centers for Disease Control and Prevention; 2007. Abstract 005."},{"key":"key-10.3201\/eid1402.070499-201211051415-R25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajog.2004.01.043","article-title":"Diagnoses and outcomes in cervical cancer screening: a population-based study.","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1086\/375074","article-title":"The health and economic burden of genital warts in a set of private health plans in the United States.","volume":"36","author":"Insinga","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid1402.070499-201211051415-R27","first-page":"337","article-title":"Direct medical costs for surgical and medical treatment of condylomata acuminata.","volume":"137","author":"Alam","year":"2001","journal-title":"Arch Dermatol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ajog.2004.01.042","article-title":"The health care costs of cervical human papillomavirus-related disease.","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.281.4.347","article-title":"Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing.","volume":"281","author":"Brown","year":"1999","journal-title":"JAMA"},{"key":"key-10.3201\/eid1402.070499-201211051415-R30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S0029-7844(02)02195-6","article-title":"Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries.","volume":"100","author":"Maxwell","year":"2002","journal-title":"Obstet Gynecol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/01.AOG.0000120143.50098.c7","article-title":"Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.","volume":"103","author":"Goldie","year":"2004","journal-title":"Obstet Gynecol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R32","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1001\/jama.287.18.2372","article-title":"Benefits and costs of using HPV testing to screen for cervical cancer.","volume":"287","author":"Mandelblatt","year":"2002","journal-title":"JAMA"},{"key":"key-10.3201\/eid1402.070499-201211051415-R33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S0002-9343(00)00349-1","article-title":"Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.","volume":"108","author":"Goldie","year":"2000","journal-title":"Am J Med"},{"key":"key-10.3201\/eid1402.070499-201211051415-R34","unstructured":"British Columbia Cancer Agency, Cancer Prevention Program. A population-based HPV immunization program in British Columbia: background paper. Vancouver (BC): The Agency; 2006."},{"key":"key-10.3201\/eid1402.070499-201211051415-R35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/archotol.130.11.1269","article-title":"The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data.","volume":"130","author":"Lang","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"key-10.3201\/eid1402.070499-201211051415-R36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values.","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"key-10.3201\/eid1402.070499-201211051415-R37","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1001\/jama.287.18.2382","article-title":"Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.","volume":"287","author":"Kim","year":"2002","journal-title":"JAMA"},{"key":"key-10.3201\/eid1402.070499-201211051415-R38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cncr.22751","article-title":"Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.","volume":"111","author":"Schiffman","year":"2007","journal-title":"Cancer"},{"key":"key-10.3201\/eid1402.070499-201211051415-R39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/01.AOG.0000196500.50044.ce","article-title":"Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.","volume":"107","author":"Kulasingam","year":"2006","journal-title":"Obstet Gynecol"},{"key":"key-10.3201\/eid1402.070499-201211051415-R40","unstructured":"Haupt RM. GARDASIL update. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13\u201317; Atlanta. Atlanta: Centers for Disease Control and Prevention."}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/14\/2\/07-0499_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T14:26:37Z","timestamp":1732631197000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/14\/2\/07-0499_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,2]]}},"URL":"https:\/\/doi.org\/10.3201\/eid1402.070499","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}